Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial
Authors
Thiery-Vuillemin, A.Saad, F.
Armstrong, A. J.
Oya, M.
Vianna, K. C. M.
Ozguroglu, M.
Gedye, C.
Buchschacher, G. L.
Lee, J. Y.
Emmenegger, U.
Navratil, J.
Virizuela, J. A.
Salazar, A.
Maillet, D.
Uemura, H.
Kim, J.
Lukacs, E.
Barker, L.
Degboe, A. N.
Clarke, Noel W
Affiliation
CHRU Besançon Hôpital J.Minjoz, Besançon, FranceIssue Date
2022
Metadata
Show full item recordCitation
Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna KCM, Ozguroglu M, et al. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301435.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5019Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5019Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5019